Boron tracedrug design for neutron dynamic therapeutics for LDL.
Adv Exp Med Biol
; 789: 385-389, 2013.
Article
em En
| MEDLINE
| ID: mdl-23852519
ABSTRACT
We describe our solution for removal of the low-density lipoprotein (LDL) depot contained in proteins and lipids as a 'druggable' target for atherosclerotic cardiovascular diseases by neutron dynamic therapy (NDT), which we developed using boron tracedrugs for NDT against bovine serum albumin as a model protein. Thus, we examined, among our developed boron tracedrugs, a boron-containing curcuminoid derivative UTX-51, to destroy freshly isolated human LDL dynamically under irradiated thermal neutron to obtain a decreased intensity of band of LDL treated with UTX-51 and thermal neutron irradiation in their SDS-PAGE and electrophoresis analysis. These results suggest that UTX-51 might be a novel candidate of 'beyond chemical' therapeutic agents for atherosclerotic cardiovascular disease.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Boro
/
Terapia por Captura de Nêutron de Boro
/
Lipoproteínas LDL
/
Nêutrons
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article